Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023
- PMID: 39084693
- PMCID: PMC11347006
- DOI: 10.3201/eid3009.240557
Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023
Abstract
Since 2022, Europe has had 4 cases of extensively drug-resistant Neisseria gonorrhoeae, sequence type 16406, that is resistant to ceftriaxone and highly resistant to azithromycin. We report 2 new cases from France in 2023 involving strains genetically related to the 4 cases from Europe as well as isolates from Cambodia.
Keywords: A2059G mutation; Azithromycin; Ceftriaxone; Drug-resistant; France; Neisseria gonorrhoeae; ST16406; antimicrobial resistance; bacteria; gonorrhea; penA-60.001; sexually transmitted infections; surveillance.
Figures
References
-
- Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27:1–5. 10.2807/1560-7917.ES.2022.27.24.2200455 - DOI - PMC - PubMed
-
- Maubaret C, Caméléna F, Mrimèche M, Braille A, Liberge M, Mainardis M, et al. Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023. Euro Surveill. 2023;28:1–5. 10.2807/1560-7917.ES.2023.28.37.2300456 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
